Does OptumRx Cover Mounjaro?Verified 2026 Answer — PA Criteria, Costs & Denial Fixes
Published: · Last reviewed:
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers. Last verified: May 16, 2026. Refreshed quarterly or when OptumRx revises its GLP-1 PA form.
Disclosure: The RX Index may earn a commission from sponsored provider links. We don’t provide medical advice, prescribe medication, or guarantee insurance approval.
The short answer
Often yes — public 2026 OptumRx formulary examples we checked list Mounjaro as a Tier 2 drug with prior authorization and quantity limits when used under the type 2 diabetes pathway. No for weight loss — the OptumRx GLP-1 obesity pathway we reviewed lists Wegovy, Zepbound, Saxenda, and generic liraglutide. Mounjaro is not on that list, because it’s FDA-approved only for diabetes.
We pulled four public 2026 OptumRx formulary documents and the actual OptumRx GLP-1 Prior Authorization Form (Revision 04/2026, TennCare-hosted) to write this. Your specific plan still has the final word.
What we actually verified
- ✓OptumRx GLP-1 Agonists Prior Authorization Form, Revision 04/2026 (TennCare-hosted public OptumRx-administered PA example)
- ✓OptumRx 2026 Non-Medicare Comprehensive Formulary (commercial example)
- ✓OptumRx 2026 State of Michigan Premium Standard Formulary (employer example)
- ✓OptumRx Select Standard Formulary, effective Jan 1, 2026 (commercial example)
- ✓OptumRx 2026 Medicare Comprehensive Formulary (Medicare Part D example)
- ✓OptumRx Select PA/QL list, effective Jan 1, 2026
- ✓Mounjaro FDA prescribing information (2026 label)
- ✓Eli Lilly Mounjaro list price ($1,112.16/fill) and Savings Card terms
- ✓CMS Medicare GLP-1 Bridge announcement (effective July 1, 2026)
- ✓OptumRx CHAMPVA coverage page and VA Meds by Mail current language
What we did not verify: your specific plan’s live formulary, your employer’s carve-outs, or live member-portal pricing. Those still matter — we’ll show you how to check them in five minutes.
Match your situation in one table
OptumRx coverage for Mounjaro turns on three factors: your diagnosis, your specific plan, and whether you’ve already tried a “preferred” GLP-1 first.
| Your situation | Likely outcome on OptumRx | Your best next step |
|---|---|---|
| Type 2 diabetes + documented qualifying lab value + your plan lists Mounjaro | ✅ Possible approval with PA | Bring the PA prep checklist below to your prescriber |
| Type 2 diabetes + no preferred GLP-1 tried yet | ⚠️ Step-therapy denial likely on the first try | If you had intolerance, contraindication, or a prior trial, make sure that history is documented |
| Weight loss only — no diabetes diagnosis | ❌ Denied. Mounjaro isn’t on the OptumRx obesity pathway we reviewed | Ask your doctor about Zepbound — the FDA-approved tirzepatide for weight management |
| You were covered before, now denied | ⚠️ Usually a PA expiration, formulary change, or pharmacy claim issue | Pull the denial letter — the fix depends on the exact reason |
| Medicare, CHAMPVA, or other government insurance | Special rules apply (see the government section) | Check your plan documents before doing anything else |
Source: OptumRx GLP-1 Agonists PA Form Rev 04/2026; OptumRx 2026 Non-Medicare Comprehensive Formulary; OptumRx CHAMPVA page; VA Meds by Mail coverage list.
Verify your specific OptumRx plan in 90 seconds
Before you chase a prior authorization, find out exactly where your plan stands. Ro’s free GLP-1 Insurance Coverage Checker contacts your insurer and sends a personalized report showing what’s covered, whether prior authorization is required, and available cost estimates for Mounjaro, Zepbound, Wegovy, and other GLP-1s. Free. No signup. Takes about 90 seconds.
Check my coverage with Ro’s free GLP-1 Insurance Checker →Sponsored affiliate link. Ro’s checker is built for commercial insurance. If you have Medicare, Medicaid, TRICARE, or CHAMPVA, skip to the government-plan section — Ro states it can’t help coordinate GLP-1 coverage for most government plans (FEHB is an exception).
What public 2026 OptumRx documents show for Mounjaro
On every commercial document we pulled, Mounjaro appears as Tier 2 (preferred brand) with prior authorization and a quantity limit. One public OptumRx Medicare formulary also shows Mounjaro at Tier 2 with QL of 2 mL per 28 days. Zepbound’s status varies more — covered on some plans, excluded on others.
| OptumRx document checked | Mounjaro status | Zepbound status | Source |
|---|---|---|---|
| 2026 Non-Medicare Comprehensive Formulary (commercial example) | Tier 2, PA, QL | Tier 3, PA, QL | contenthub-aem.optumrx.com |
| 2026 State of Michigan Premium Standard Formulary (employer example) | Tier 2, PA, QL | Marked "E" (excluded) | contenthub-aem.optumrx.com |
| OptumRx Select Standard Formulary, Jan 1, 2026 (commercial example) | Tier 2, PA, QL | Listed in index — plan-specific check required | business.optum.com |
| OptumRx 2026 Medicare Comprehensive Formulary (Medicare Part D example) | Tier 2, PA, QL (2 mL per 28 days) | Plan-specific | contenthub-aem.optumrx.com |
| OptumRx Select PA/QL List, Jan 1, 2026 | Listed with quantity limit on select-plan PA/QL guidance | GLP-1 class limits apply | business.optum.com |
All documents accessed and verified May 16, 2026.
Mounjaro is consistently coverable — but never automatically.
Every formulary we pulled listed Mounjaro at Tier 2 with prior authorization required. There's no OptumRx plan we found where you can walk in, hand over your card, and get Mounjaro filled without PA. The PA is the gate.
Quantity limits are real and dose-specific.
The public OptumRx Medicare example shows Mounjaro QL at 2 mL per 28 days — which equals four 0.5 mL pens, one per week, exactly the FDA-labeled dose. If you try to escalate your dose faster than 4 weeks at a level, or refill early because you traveled, the QL can trigger a rejection at the pharmacy counter even when your PA is approved.
Don't assume Mounjaro and Zepbound have the same coverage.
They're the same molecule (tirzepatide), made by the same company (Eli Lilly), but OptumRx treats them as completely different drugs because their FDA indications are different. We saw one plan where Mounjaro was Tier 2 and Zepbound was fully excluded.
The plan-document caveat: Every OptumRx formulary we pulled includes some version of this: “Coverage is determined by your prescription medication benefit plan. When differences between this list and your benefit plan documents exist, please refer to the information included in your benefit plan documents.” A public OptumRx formulary tells you what OptumRx generally does. Your employer can carve things out, add step therapy, or exclude a drug class entirely.
What PA, QL, ST, and “E” mean on your OptumRx formulary
These four letters appear next to almost every GLP-1 on every OptumRx formulary. Insurance jargon is the problem, not you.
| Code | What it means | What it means for Mounjaro | Exact question to ask OptumRx |
|---|---|---|---|
| PA | Prior authorization. Your doctor has to submit extra paperwork before OptumRx will pay. | Required for Mounjaro on essentially every OptumRx plan we've reviewed. | "What diagnosis and documentation does my plan require for Mounjaro PA?" |
| QL | Quantity limit. OptumRx caps how much you can get in a certain period. | The OptumRx Medicare example shows QL of 2 mL per 28 days. Your plan's exact limit may differ. | "What numeric quantity limit applies to my dose and fill schedule?" |
| ST | Step therapy. You have to try (and fail) a cheaper drug first. | On many OptumRx plans, you'll need to show you tried Ozempic, Trulicity, or another preferred GLP-1 before Mounjaro will be approved. | "Which preferred drugs must be tried first, and what counts as intolerance or treatment failure?" |
| E | Excluded (or excluded unless you get a formulary exception). | Some employer plans exclude Mounjaro or the whole weight-loss GLP-1 class. This is the hardest denial to overturn. | "Is this a true exclusion, or can my prescriber request a formulary exception?" |
If Mounjaro shows up with “PA, QL” next to it — that’s the most common pattern, and it’s fully approvable for the right diagnosis. “PA, QL, ST” means you’ll also need to document failed prior GLP-1s. “E” means you’ll need to fight harder, switch drugs, or pay cash.
OptumRx prior authorization criteria for Mounjaro (from the 04/2026 form)
OptumRx requires PA for Mounjaro on essentially every plan. To get approved under the diabetes pathway, your prescriber has to document a type 2 diabetes diagnosis with one of four qualifying lab values, no concurrent GLP-1 use, no personal or family history of medullary thyroid cancer or MEN2, an attestation that you’re making lifestyle changes, and proof that you tried a preferred GLP-1 first.
The four lab values that qualify you (you only need ONE)
HbA1c ≥ 6.5%
Most flexible criterion. The form explicitly notes: if original HbA1c is unknown, or current HbA1c is controlled due to another current diabetic regimen, please include current regimen and current HbA1c.
Fasting plasma glucose ≥ 126 mg/dL
Two-hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test
Random plasma glucose ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis
Practical tip most patients miss: if you’re already on a diabetes regimen that controlled your A1C below 6.5%, that doesn’t disqualify you. You can submit your earliest documented A1C (the one that established the diagnosis), along with your current regimen and current A1C. Many denials at this step happen because the prescriber only submits the current (controlled) A1C with no historical context.
The seven questions every Mounjaro PA must answer
What's the diagnosis?
Options: Type 2 Diabetes / Obesity Management Therapy / CV Risk Reduction / OSA / NASH-MASH / Other. Mounjaro can only be approved under Type 2 Diabetes, NASH-MASH (strict criteria), or Other-with-justification. It is not an approvable answer under Obesity Management Therapy.
Will it be used with another GLP-1?
Must be no.
Will it be used with a DPP-4 inhibitor like Janumet or Tradjenta?
Generally no.
Do you (or an immediate family member) have a history of medullary thyroid carcinoma or MEN2?
Must be no. This is an FDA boxed-warning contraindication.
Are you participating in nutritional and lifestyle changes?
Must be yes. Your prescriber has to attest to this.
Any other relevant info.
Have you tried a preferred GLP-1 first?
This is the step-therapy gate. Preferred GLP-1s on the form: Ozempic, Victoza, Wegovy, Zepbound, Rybelsus, Saxenda, Soliqua, Trulicity, and Xultophy. Mounjaro is listed as non-preferred. Your prescriber has to list what you tried, how long, and why you stopped.
Your printable PA prep checklist
This is the single highest-leverage thing you can do before your prescriber submits the PA.
Bring to the appointment:
- ☐Your most recent A1C result
- ☐Your earliest documented A1C (or fasting glucose ≥126, 2-hour glucose ≥200, or random glucose ≥200 with symptoms)
- ☐A list of every diabetes medication you've ever taken, with start/stop dates and the reason you stopped each one
- ☐Documentation of any side effects or intolerance from prior GLP-1s (especially Ozempic, Trulicity, or Wegovy)
- ☐A note about your lifestyle changes — diet, exercise, weight management program
- ☐Confirmation that you have no personal or family history of MTC or MEN2
- ☐Your insurance card with OptumRx info visible
Ask your prescriber to:
- ☐Submit the PA electronically (CoverMyMeds or ePA), not by fax
- ☐Use ICD-10 code E11.x only if Type 2 diabetes is accurately documented in your medical record
- ☐Document the step-therapy history in the “Length of trial / Reason for discontinuation” fields
- ☐Attest to lifestyle counseling and the relevant lab values
- ☐Request expedited review if your A1C is dangerously high or your diabetes is poorly controlled
Want a provider visit where they actually help with the PA paperwork?
Some patients have a great endocrinologist who handles the PA in their sleep. Others have a primary care doctor who’ll write the prescription but isn’t going to sit on hold with OptumRx for an hour. Sesame Care lists Mounjaro in its medication catalog, and Sesame’s page states that a Sesame provider can assist with prior authorization paperwork when insurance is involved. Visits are transparent flat-fee.
See Mounjaro providers and PA help on Sesame Care →Sponsored affiliate link. Sesame visits don’t guarantee OptumRx approval — they help with the paperwork, but the final decision still belongs to your plan.
How long can an OptumRx Mounjaro prior authorization take?
Timing depends on the plan, submission method, and whether OptumRx needs more records. Commercial drug PA turnaround typically runs 1 to 14 days depending on plan rules, ePA submission, and documentation completeness.
Best case
Minutes
Electronic submission, complete documentation, automated PreCheck match
Typical case
1–7 days
Commercial plans; varies by ePA submission and documentation completeness
Worst case
7–14 days
Fax submission, missing documentation, complex history, request for additional records
How to make it faster: Submit electronically through CoverMyMeds, Surescripts, or your prescriber’s ePA system. Send all supporting documentation in the first submission. Ask your prescriber to request expedited review if your blood sugar is dangerously high, you have diabetic complications, or your current regimen has failed. Track status at optumrx.com or the OptumRx app.
OptumRx’s PA submission line for most plans: 1-800-711-4555. Electronic submission through CoverMyMeds is faster and we strongly recommend it over fax.
Will OptumRx cover Mounjaro for weight loss? The hard truth most pages get wrong
Answer: No.
The OptumRx GLP-1 Agonists PA Form (Rev 04/2026) lists exactly four medications under Obesity Management Therapy: Wegovy, Saxenda, generic liraglutide for Saxenda, and Zepbound. Mounjaro is not on that list. Even if you meet the BMI criteria, the form has no question that pairs Mounjaro with obesity. The PA will be denied at the criteria-mismatch level.
Why so many pages say “yes, via Zepbound criteria” — and why they’re wrong
The reasoning sounds plausible: Mounjaro and Zepbound contain the same active ingredient (tirzepatide), made by Eli Lilly, at the same doses. Writers assume the criteria transfer.
They don’t. The OptumRx PA form is structured by drug name. When the prescriber submits a PA for Mounjaro under Obesity Management Therapy, the form routes them to Question 11 — which explicitly lists only Saxenda, generic liraglutide, Wegovy, and Zepbound. Mounjaro is not in the list. The PA gets denied not because the patient doesn’t meet BMI criteria — they might — but because the drug-and-diagnosis combination has no approval pathway on the form.
The honest path forward if you want tirzepatide for weight loss
If you’ve been using Mounjaro off-label and OptumRx is denying it, the structurally cleaner answer is Zepbound. Same molecule. Same dosing. Same once-weekly injection. But Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea, and OptumRx has a documented PA pathway for it.
To qualify for Zepbound on OptumRx, you’ll generally need:
- BMI ≥ 30, OR BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, MASH/NASH, or sleep apnea)
- Documented participation in dietary and lifestyle changes
- No concurrent use of another weight-loss medication
- For some plans: step therapy through phentermine or a less expensive weight-loss medication first
If your OptumRx denied Mounjaro because it’s for weight loss, this is your real answer
Zepbound is the FDA-approved tirzepatide for weight management. Same active ingredient as Mounjaro, same manufacturer, but with the FDA approval and the OptumRx coverage pathway that actually works for weight loss.
Ro carries Zepbound (pen and KwikPen), Foundayo, Wegovy pill, Wegovy pen, and Ozempic. Their insurance concierge handles the OptumRx PA on your behalf. And the free GLP-1 Insurance Coverage Checker tells you what your plan covers before you commit. Ro Body membership: $39 for the first month, then as low as $74/month with annual plan paid upfront (or $149/month month-to-month). Medication billed separately.
Check Zepbound coverage with Ro’s free Insurance Checker →Sponsored affiliate link. Note: Ro does NOT carry Mounjaro itself. Ro’s current pricing page lists Wegovy pill, Foundayo, Zepbound KwikPen, Wegovy pen, and Ozempic. If you specifically need Mounjaro filled for documented type 2 diabetes, Sesame Care is the cleaner linked path.
One ethical line we need to draw: We’ve seen pages and forum posts suggest asking your prescriber to “just code it as diabetes” so OptumRx will pay for Mounjaro when you actually want it for weight loss. Don’t do that. Coding a diagnosis that isn’t in your medical record is insurance fraud, full stop. The honest path is the same molecule, the right label, and a PA your plan can actually approve.
What you’ll actually pay for Mounjaro with OptumRx
The verified facts: Lilly’s list price is $1,112.16 per fill (per pricinginfo.lilly.com); the Lilly Savings Card can drop the cost to $25/month for eligible commercially insured patients whose plan covers Mounjaro; the 2026 Medicare Part D annual out-of-pocket cap is $2,100 for covered drugs. Public OptumRx formularies prove tier and PA/QL status, but your member portal shows your live copay.
| Your scenario | What we can say with confidence | Notes |
|---|---|---|
| Commercial OptumRx, Mounjaro covered, deductible met | Plan-specific copay or coinsurance after PA. Typical Tier 2 copays for brand drugs run roughly $25–$75/month. | The Lilly Savings Card can reduce eligible commercial-insurance costs to as low as $25/month. |
| Commercial OptumRx, before deductible | Plan-specific. High-deductible plans may expose more list-price cost until the deductible or benefit rules apply. | The Savings Card still helps. |
| Medicare Part D, T2D + covered drug | Plan-specific monthly cost. The verified 2026 federal number is the $2,100 annual Part D out-of-pocket threshold for covered drugs. | Lilly Savings Card NOT usable for Medicare patients (federal anti-kickback rules). |
| Medicaid (state-dependent), T2D + approved PA | State-specific. Check your state PDL, PA criteria, and copay rules. | Most state Medicaid programs cap copays at very low amounts. |
| Plan excludes GLP-1s entirely | Roughly Lilly's $1,112 list price unless you qualify for Savings Card uninsured-tier or use cash-pay routes | Savings Card may help if you have commercial insurance but it doesn't cover Mounjaro — drops cost as low as $499/month. |
| No insurance at all | Potentially close to Lilly's list price plus pharmacy markup | Savings Card is NOT available to uninsured patients. |
Sources: Lilly Mounjaro pricing page (pricinginfo.lilly.com); Mounjaro Savings Card terms (mounjaro.lilly.com/savings-resources); CMS 2026 Part D OOP cap. Verified May 16, 2026.
How the Lilly Mounjaro Savings Card actually works
Commercial insurance + plan covers Mounjaro
As low as $25/month
Up to $1,950 in annual savings, up to 13 fills per calendar year
Commercial insurance but plan does NOT cover Mounjaro
Up to $499/month savings
Up to $8,411 in annual savings, max 13 fills per year
Medicare, Medicaid, TRICARE, CHAMPVA, VA, or uninsured
Not eligible
Federal anti-kickback rules apply. Card savings end December 31, 2026.
Denied by OptumRx? Here’s the appeal path that actually works
A first-pass Mounjaro denial from OptumRx can be fixable when caused by missing documentation, step therapy history, or diagnosis mismatch. You have 180 days from the denial letter date to file an internal appeal under federal law. If the internal appeal fails, you have a right to a free external review by an Independent Review Organization. Open your denial letter, find the “Reason for denial,” and match it to the table below.
| Denial reason on your letter | What it actually means | Your fix |
|---|---|---|
| Step therapy not met | You haven't documented trying a preferred GLP-1 first (usually Ozempic, Trulicity, or Wegovy) | Submit pharmacy records showing prior GLP-1 fills with start/stop dates and reason for discontinuation. If you can't tolerate a preferred drug due to side effects, document that specifically and request a step-therapy exception. |
| Insufficient documentation of T2D diagnosis | The submitted chart notes don't clearly establish type 2 diabetes | Resubmit with an explicit HbA1c lab result (≥6.5%) and ICD-10 code E11.x. Add chart notes about ongoing diabetes management. Include the earliest documented A1C, not just the current one. |
| Not on formulary / non-formulary exception denied | Your specific employer plan has tighter rules than the standard OptumRx framework | Request a formulary exception with a letter of medical necessity. Cite specific clinical evidence for tirzepatide and explain why preferred alternatives are inappropriate for you. |
| Off-label use for weight loss | The diagnosis on the PA was obesity or BMI-related rather than T2D | If you genuinely have T2D, resubmit with the T2D diagnosis. If you don't, ask your prescriber about Zepbound — same molecule, FDA-approved indication for weight loss, separate (and approvable) PA path. |
| Weight-loss exclusion (plan-level) | Your employer chose to exclude all weight-loss medications | This is the hardest denial to overturn. If you have a documented comorbidity that creates medical necessity beyond weight loss (sleep apnea, cardiovascular risk), an external review can still succeed — but it's harder than fixing a documentation problem. |
The internal appeal letter that works
Your appeal letter should do four things, in this order:
- Reference the denial letter directly. Include the claim number, denial date, and the exact denial reason quoted from the letter.
- Cite the OptumRx criteria you meet — quoted from your plan documents, not paraphrased.
- Attach the evidence the original PA missed. Lab results, chart notes, prior medication history with dates, prescriber letter of medical necessity.
- Request a peer-to-peer review if the denial was clinical. Your prescriber speaks directly to an OptumRx clinical pharmacist — this often overturns denials that look bulletproof on paper.
Most Part D plans have 30 days to decide an internal appeal (72 hours for expedited). Commercial timelines vary by plan.
When to escalate to external review
If your internal appeal is denied, the law gives you a right to an Independent Review Organization (IRO) external review at no cost to you. The IRO is independent of OptumRx. Most states have a 4-month deadline from the final internal denial. External review can be powerful when the denial is clinical and your documentation directly supports the plan’s criteria. It rarely overturns straight benefit exclusions.
Mounjaro through Medicare, Medicaid, CHAMPVA, and TRICARE
Medicare Part D (including UHC Medicare Advantage + OptumRx)
- Mounjaro is generally covered for type 2 diabetes with prior authorization. One public 2026 OptumRx Medicare formulary example lists Mounjaro as Tier 2 with PA and QL of 2 mL per 28 days.
- The verified 2026 federal number: Part D annual out-of-pocket threshold of $2,100 for covered drugs.
- Mounjaro is NOT on the 2026 Medicare GLP-1 Bridge list (which covers Wegovy, Zepbound KwikPen, and Foundayo at $50/month from July 1, 2026).
- Lilly Savings Card not available for Medicare patients — federal anti-kickback rules prohibit manufacturer copay assistance for government beneficiaries.
- Medicare Prescription Payment Plan (M3P): Spreads covered out-of-pocket prescription drug costs across the calendar year. It does not lower the cost — it changes the timing. Free opt-in through any Part D plan.
Medicaid (state-dependent)
Medicaid coverage is state-dependent. In the TennCare OptumRx documents we reviewed, Mounjaro appears as a non-preferred GLP-1 with PA and QL. Almost no Medicaid program covers Mounjaro for weight loss. The most common denial pattern in public Medicaid appeal examples: diagnosis mismatch and missing documentation. See our guide on Does Medicaid Cover Wegovy? for the Medicaid GLP-1 landscape.
CHAMPVA
OptumRx’s CHAMPVA page is explicit: Since January 1, 2025, CHAMPVA covers Mounjaro and Ozempic only with a confirmed type 2 diabetes diagnosis. The page specifically excludes coverage for prediabetes, weight loss, or obesity.
Current VA Meds by Mail language: Mounjaro is only covered with a type 2 diabetes diagnosis; Wegovy is only covered with a diagnosis for prevention of major adverse cardiovascular events; Zepbound is only covered with an obstructive sleep apnea diagnosis. Don’t treat CHAMPVA weight-loss GLP-1 coverage like a normal commercial-plan exception hunt.
TRICARE
TRICARE uses Express Scripts, not OptumRx, for pharmacy benefits. If you’re on TRICARE, the OptumRx rules on this page don’t apply directly to you.
If you have a government plan, do not start with a third-party provider service before checking your own plan’s coverage. Ro states its insurance concierge currently can’t help coordinate GLP-1 coverage for most government insurance plans (with an FEHB exception). Your first step: check your OptumRx member portal or member services for Mounjaro coverage; call the number on your member card and ask the specific PA criteria; have your existing prescriber submit the PA.
Mounjaro vs. Zepbound on OptumRx — they are not interchangeable for coverage
Mounjaro and Zepbound are the same molecule (tirzepatide), made by Eli Lilly, at the same doses. For OptumRx coverage purposes, they are completely different drugs. The PA forms route them differently. Asking for Mounjaro when you need the weight-loss path is the most preventable cause of denial.
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| FDA-approved for | Type 2 diabetes (adults + pediatric 10+) | Chronic weight management; obstructive sleep apnea |
| OptumRx PA pathway | Question 8 (T2D); Question 10 (NASH/MASH coverage-form pathway) | Question 11 (Obesity); Question 12 (OSA) |
| Required documentation | HbA1c ≥6.5% or equivalent diabetes lab | BMI ≥30 or ≥27 with comorbidity |
| Step therapy on OptumRx | Yes — non-preferred on the reviewed form | Yes — varies by plan |
| Lilly Savings Card | $25/mo if covered, up to $499/mo if uncovered | $25/mo if covered, up to $620/mo if uncovered |
| Cash price (2026) | ~$1,112/month (Lilly list) | ~$1,060/month (Lilly list) |
The bottom line: if your goal is diabetes management, ask about Mounjaro. If your goal is weight loss, ask about Zepbound. They’re not interchangeable for insurance purposes, even though they’re medically the same molecule.
Real-world denial example — what actually happens
Case: The diagnosis-mismatch denial
Source: MassHealth Board of Hearings, Appeal No. 2302617, public record.
A MassHealth member submitted a PA request for Mounjaro 5 mg/0.5 ml pen on March 8, 2023. The diagnosis listed on the PA was obesity. MassHealth denied the request, citing the explicit Medicaid policy: “MassHealth does not pay for any drug used for the treatment of obesity.” The appeal was denied. The hearing officer noted that if the appellant had been diagnosed with diabetes, the prescriber should have consulted the MassHealth Drug List for the type 2 diabetes prior authorization requirements for Mounjaro.
The lesson: Same drug, same medication request, wrong coverage pathway. The leverage point is matching the request to an accurate documented diagnosis and the correct coverage pathway — not changing codes to chase approval.
Provider-stated vs. verified — what the companies we mention actually say
| Claim | Source | Verification status | Practical caveat |
|---|---|---|---|
| Ro's GLP-1 Insurance Coverage Checker contacts the insurer and sends a personalized report | ro.co/weight-loss/glp1-insurance-checker | Provider-stated, verified May 16, 2026 | Not a prescription, PA submission, or treatment request |
| Ro membership pricing: $39 first month, then as low as $74/month with annual prepay or $149/month month-to-month | ro.co/weight-loss/pricing | Provider-stated, verified May 16, 2026 | Medication billed separately |
| Ro cannot coordinate GLP-1 coverage for most government insurance plans (FEHB exception noted) | ro.co/weight-loss/pricing | Provider-stated, verified May 16, 2026 | Government-plan readers should start with member services |
| Ro's pricing page lists Wegovy pill, Foundayo, Zepbound KwikPen, Wegovy pen, and Ozempic — not Mounjaro | ro.co/weight-loss/pricing | Provider-stated, verified May 16, 2026 | If you need Mounjaro specifically, Sesame is the linked path |
| Sesame provider can assist with Mounjaro prior authorization paperwork | sesamecare.com/medication/mounjaro | Provider-stated, verified May 16, 2026 | Does not guarantee OptumRx approval |
| Sesame lists Mounjaro pens at roughly $1,080–$1,300/month without insurance | sesamecare.com/medication/mounjaro | Provider-stated, verified May 16, 2026 | Pharmacy price may change |
| Lilly Mounjaro list price is $1,112.16 per fill | pricinginfo.lilly.com/mounjaro | Manufacturer-stated, verified May 16, 2026 | Patient cost depends on plan, pharmacy, and discounts |
| Lilly Savings Card terms: $25/mo with covered commercial insurance; up to $499/mo savings if commercial uncovered; program savings end Dec 31, 2026 | mounjaro.lilly.com/savings-resources | Manufacturer-stated, verified May 16, 2026 | Not available to Medicare, Medicaid, TRICARE, CHAMPVA, VA, or uninsured |
Should you use Ro, Sesame Care, or your own doctor for this?
| Your situation | Best route | Why |
|---|---|---|
| You have a good endocrinologist or PCP who'll handle the PA | Your own doctor | Continuity, history, and they already have your labs |
| You have commercial insurance and want to verify coverage before doing anything | Ro Coverage Checker | Free, takes 90 seconds, gives a personalized coverage report |
| You want a telehealth provider visit specifically for Mounjaro, including PA help | Sesame Care | Sesame lists Mounjaro in its formulary and offers PA paperwork assistance |
| Your Mounjaro denial revealed you actually need Zepbound (off-label weight loss) | Ro for Zepbound | Ro carries Zepbound, matches LillyDirect pricing, and runs the PA for you |
| You're on Medicare, Medicaid, CHAMPVA, TRICARE, or VA | Your existing prescriber + plan member services | Most telehealth providers can't coordinate government insurance for GLP-1s |
| Plan flat-out excludes all weight-loss GLP-1s and you have no T2D | Review cash-pay alternatives | Cash-pay paths and alternatives are situation-specific |
How to check your specific OptumRx Mounjaro coverage in 5 minutes
Log into your OptumRx account or app
Go to optumrx.com or download the OptumRx mobile app. Sign in and search for Mounjaro by name. Write down: Is Mounjaro listed? What tier? Does it show PA? QL? ST? Or “E” (excluded)? What’s the estimated price at your preferred pharmacy? Is home delivery vs. retail priced differently? Are 30-day and 90-day fills both allowed?
Call OptumRx member services with this exact script
“Hi, I’m checking coverage for Mounjaro under my current pharmacy benefit. Can you tell me: 1) Is Mounjaro on my formulary? 2) What tier is it? 3) Does it require prior authorization? 4) Is there step therapy I have to complete first? 5) Is there a quantity limit? 6) What diagnosis or documentation does my plan require for approval? 7) Is Mounjaro covered only for type 2 diabetes on my plan, or can it be covered for any other condition?”
Fill in the OptumRx call log while on the phone
| Field | Your answer |
|---|---|
| Date called | ___________ |
| Rep name / ID number | ___________ |
| Formulary status (covered or not) | ___________ |
| Tier | ___________ |
| PA / QL / ST / E flags | ___________ |
| Diagnosis requirement | ___________ |
| Step therapy drugs required first | ___________ |
| Quantity limit (numeric) | ___________ |
| PA submission method (CoverMyMeds, fax, phone) | ___________ |
| Reference number for this call | ___________ |
Confirm where the PA should be submitted
Ask: “Should my prescriber submit the prior authorization through CoverMyMeds, your ePA portal, or by fax?” OptumRx’s PA submission line for most plans is 1-800-711-4555. Electronic submission through CoverMyMeds is faster.
Before your doctor submits the PA, confirm four things
- Formulary status (covered or excluded)
- Diagnosis requirement (T2D only, or broader)
- Step therapy requirement (which preferred drugs must be tried first)
- Quantity limit (numeric, on your specific plan)
Frequently asked questions
- Does OptumRx cover Mounjaro?
- Often yes, for type 2 diabetes. The public 2026 OptumRx formularies we checked list Mounjaro as Tier 2 with prior authorization and quantity limits when used under the diabetes pathway. Your specific plan's benefit documents control the final answer.
- Does OptumRx cover Mounjaro for weight loss?
- No for a clean weight-loss-only Mounjaro request under the OptumRx GLP-1 obesity pathway we reviewed. Only Wegovy, Saxenda, generic liraglutide, and Zepbound are listed for obesity management. The FDA-approved tirzepatide for weight loss is Zepbound, which OptumRx has a documented PA pathway for.
- What diagnosis does OptumRx require for Mounjaro?
- Type 2 diabetes mellitus, documented by an HbA1c ≥6.5%, fasting plasma glucose ≥126 mg/dL, two-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test, or random plasma glucose ≥200 mg/dL with classic hyperglycemia symptoms. The PA form (Revision 04/2026) allows any one of these four to qualify.
- What tier is Mounjaro on OptumRx?
- Tier 2 on the public commercial and Medicare OptumRx formularies we checked, including the 2026 Non-Medicare Comprehensive Formulary, the 2026 State of Michigan Premium Standard Formulary, the OptumRx Select Standard Formulary, and one 2026 OptumRx Medicare Comprehensive Formulary. Your specific plan may differ — check your member portal.
- How long does OptumRx prior authorization take for Mounjaro?
- Timing depends on the plan, submission method, and whether OptumRx needs more records. The TennCare OptumRx GLP-1 form we reviewed says PA requests get a response within 24 hours upon receipt; that is TennCare-specific. Commercial drug PA turnaround typically runs 1 to 14 days. Electronic submission is faster than fax. Expedited reviews are available for clinically urgent cases.
- Why did OptumRx deny my Mounjaro prescription?
- The five most common reasons are: step therapy not met (you haven't tried a preferred GLP-1 first), insufficient documentation of T2D diagnosis, off-label use for weight loss, plan-level exclusion of GLP-1s, or a pharmacy billing error. Your denial letter will list the specific reason.
- Can I appeal an OptumRx Mounjaro denial?
- Yes. Federal law gives you 180 days from the denial date to file an internal appeal. If denied internally, you have a right to a free external review by an Independent Review Organization. Appeals work best when they respond to the exact denial reason on the letter rather than making a general medically necessary argument.
- How much does Mounjaro cost with OptumRx coverage?
- Your cost depends on your plan's tier, deductible, copay or coinsurance, pharmacy channel, PA approval, and Lilly Savings Card eligibility. The verified facts: Lilly's list price is $1,112.16 per fill; the Lilly Savings Card can drop the cost to $25/month for eligible commercially insured patients whose plan covers Mounjaro; the 2026 Medicare Part D annual out-of-pocket cap is $2,100 for covered drugs.
- Does OptumRx cover Mounjaro if I only have prediabetes?
- Generally no. Mounjaro's FDA indication is type 2 diabetes, not prediabetes. The PA form requires lab values that establish T2D, not prediabetic ranges. Ask your prescriber whether a different FDA-approved medication better matches your condition.
- Is the Mounjaro Savings Card usable with OptumRx?
- Yes — if you have commercial OptumRx coverage and your plan covers Mounjaro, the Lilly Mounjaro Savings Card can drop your cost as low as $25/month (subject to eligibility rules). The card is not available to anyone on Medicare, Medicaid, TRICARE, CHAMPVA, or the VA.
- Does Medicare cover Mounjaro through OptumRx?
- Yes for type 2 diabetes with prior authorization on Medicare Part D plans administered by OptumRx. No for weight loss — federal law prohibits Medicare from covering medications prescribed for weight loss. Mounjaro is not on the 2026 Medicare GLP-1 Bridge list, which covers Wegovy, Zepbound KwikPen, and Foundayo at $50/month starting July 1, 2026.
- Does CHAMPVA cover Mounjaro?
- OptumRx's CHAMPVA page states that, since January 1, 2025, CHAMPVA covers Mounjaro and Ozempic only with a confirmed type 2 diabetes diagnosis. Wegovy is covered with a diagnosis for prevention of major adverse cardiovascular events, and Zepbound is covered with an obstructive sleep apnea diagnosis.
- Is Zepbound covered if Mounjaro isn't?
- It depends on your plan. Some public OptumRx formularies cover both Mounjaro and Zepbound (with PA on each). Others cover Mounjaro for diabetes but exclude Zepbound for weight management entirely — as seen in the State of Michigan Premium Standard Formulary. Check your specific plan.
- What's the difference between OptumRx and UnitedHealthcare?
- UnitedHealthcare (UHC) is a health insurance company. OptumRx is its pharmacy benefit manager. Both are owned by UnitedHealth Group. UHC handles your medical coverage; OptumRx processes your prescription drug claims. OptumRx also serves many non-UHC employer plans — you can be on OptumRx without having UHC as your medical insurer.
How we verified this page
OptumRx documents
- GLP-1 Agonists PA Form, Revision 04/2026 (TennCare-hosted)
- 2026 Non-Medicare Comprehensive Formulary
- 2026 State of Michigan Premium Standard Formulary
- Select Standard Formulary, Jan 1, 2026
- 2026 Medicare Comprehensive Formulary
- Select PA/QL List, Jan 1, 2026
- CHAMPVA coverage page
FDA, Lilly & government sources
- Mounjaro (tirzepatide) Prescribing Information, 2026 label
- Mounjaro list price ($1,112.16/fill) — pricinginfo.lilly.com
- Mounjaro Savings Card terms — mounjaro.lilly.com
- CMS 2026 Part D Redesign Program Instructions ($2,100 OOP cap)
- CMS Medicare GLP-1 Bridge announcement, effective July 1, 2026
- VA Meds by Mail covered medications list
- MassHealth Board of Hearings, Appeal No. 2302617 (public record)
What we did not verify: your specific plan’s live formulary or member-portal pricing; your employer’s individual carve-outs; your specific PA approval criteria; live promotional pricing on provider sites; that every commercial OptumRx plan follows the exact criteria on the TennCare-hosted PA form.
We separated three kinds of claims throughout this page: (1) Verified commercial facts — formulary tiers, PA codes, quantity limits, list prices, Savings Card terms — sourced from current public documents. (2) Medical and regulatory facts — FDA indications, PA lab thresholds, contraindications — sourced from FDA labels and OptumRx PA form criteria. (3) Editorial judgments — which provider fits which reader — explicitly framed as our recommendations based on the verified facts above.
We update this page quarterly, on January 1 and July 1 each year (when OptumRx formularies revise), and immediately when there’s a major Lilly pricing change, OptumRx PA form revision, or government policy update.
Last verified, sources, and disclosures
Published: · Last reviewed:
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers.
Affiliate disclosure. The RX Index may earn affiliate commissions on some links to Ro and Sesame Care when readers sign up. Affiliate relationships do not change the formulary tiers, PA criteria, lab thresholds, or appeal pathways presented above — those come from primary OptumRx and FDA sources.
Medical disclaimer. We don’t provide medical advice. Talk to your prescriber about whether Mounjaro is right for your situation. Information about OptumRx programs is summarized in plain English and may not capture every individual exception — confirm details with OptumRx member services or your plan documents.